Document is current
Any future updates will be listed below
-
Authors
Godown, Justin
Kim, Emily H.
Everitt, Melanie D.
Chung, Wendy K.
Lytrivi, Irene D.
Kirmani, Sonya
Kantor, Paul F.
Ware, Stephanie M.
Ballweg, Jean A.
Lal, Ashwin K.
Bansal, Neha
Towbin, Jeffrey
Lipshultz, Steven E.
Lee, Teresa M.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL53392)
National Institutes of Health (HL139968)
Children's Cardiomyopathy Foundation
Kyle John Rymiszewski Foundation
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 11 April 2024
First Online: 7 May 2024
Declarations
:
: Justin Godown is employed by BioMarin Pharmaceutical and has stock in Abbott. Steven Lipshultz reports being the chair of the Children’s Cardiomyopathy Foundation medical advisory board and their Chief Medical Officer. Steven Lipshultz is also on the medical advisory board of Secretome Therapeutics, was also a Bayer consultant, and a member of the Roche DSMB. Steven Lipshultz has also served in the following editorial roles: American College of Cardiology (Editor), Elsevier (Editor), Biomed Central (Editor), American Heart Association (Scientific Statement Chair). All other authors have no competing interests to declare that are relevant to the content of this article.
